sickle cell and thalassaemia support project (wolverhampton)
sickle cell and thalassaemia support project (wolverhampton) Company Information
Company Number
03575079
Next Accounts
Dec 2025
Shareholders
-
Group Structure
View All
Industry
Other human health activities
Registered Address
paycare house george street, wolverhampton, WV2 4DX
Website
http://sctsp.org.uksickle cell and thalassaemia support project (wolverhampton) Estimated Valuation
Pomanda estimates the enterprise value of SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON) at £153.5k based on a Turnover of £292k and 0.53x industry multiple (adjusted for size and gross margin).
sickle cell and thalassaemia support project (wolverhampton) Estimated Valuation
Pomanda estimates the enterprise value of SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON) at £111.4k based on an EBITDA of £28.7k and a 3.88x industry multiple (adjusted for size and gross margin).
sickle cell and thalassaemia support project (wolverhampton) Estimated Valuation
Pomanda estimates the enterprise value of SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON) at £1.8m based on Net Assets of £733.1k and 2.46x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Sickle Cell And Thalassaemia Support Project (wolverhampton) Overview
Sickle Cell And Thalassaemia Support Project (wolverhampton) is a live company located in wolverhampton, WV2 4DX with a Companies House number of 03575079. It operates in the other human health activities sector, SIC Code 86900. Founded in June 1998, it's largest shareholder is unknown. Sickle Cell And Thalassaemia Support Project (wolverhampton) is a mature, micro sized company, Pomanda has estimated its turnover at £292k with declining growth in recent years.
Upgrade for unlimited company reports & a free credit check
Sickle Cell And Thalassaemia Support Project (wolverhampton) Health Check
Pomanda's financial health check has awarded Sickle Cell And Thalassaemia Support Project (Wolverhampton) a 4.5 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 4 areas for improvement. Company Health Check FAQs
4 Strong
1 Regular
4 Weak
Size
annual sales of £292k, make it smaller than the average company (£727.5k)
£292k - Sickle Cell And Thalassaemia Support Project (wolverhampton)
£727.5k - Industry AVG
Growth
3 year (CAGR) sales growth of -31%, show it is growing at a slower rate (7.2%)
-31% - Sickle Cell And Thalassaemia Support Project (wolverhampton)
7.2% - Industry AVG
Production
with a gross margin of 38.3%, this company has a comparable cost of product (38.3%)
38.3% - Sickle Cell And Thalassaemia Support Project (wolverhampton)
38.3% - Industry AVG
Profitability
an operating margin of 9.8% make it more profitable than the average company (5.1%)
9.8% - Sickle Cell And Thalassaemia Support Project (wolverhampton)
5.1% - Industry AVG
Employees
with 5 employees, this is below the industry average (19)
5 - Sickle Cell And Thalassaemia Support Project (wolverhampton)
19 - Industry AVG
Pay Structure
on an average salary of £38.1k, the company has a higher pay structure (£26.5k)
£38.1k - Sickle Cell And Thalassaemia Support Project (wolverhampton)
£26.5k - Industry AVG
Efficiency
resulting in sales per employee of £58.4k, this is more efficient (£45.5k)
£58.4k - Sickle Cell And Thalassaemia Support Project (wolverhampton)
£45.5k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Sickle Cell And Thalassaemia Support Project (wolverhampton)
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Sickle Cell And Thalassaemia Support Project (wolverhampton)
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Sickle Cell And Thalassaemia Support Project (wolverhampton)
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 13921 weeks, this is more cash available to meet short term requirements (127 weeks)
13921 weeks - Sickle Cell And Thalassaemia Support Project (wolverhampton)
127 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 10.7%, this is a lower level of debt than the average (22.1%)
10.7% - Sickle Cell And Thalassaemia Support Project (wolverhampton)
22.1% - Industry AVG
SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON) financials
Sickle Cell And Thalassaemia Support Project (Wolverhampton)'s latest turnover from March 2024 is £292 thousand and the company has net assets of £733.1 thousand. According to their latest financial statements, Sickle Cell And Thalassaemia Support Project (Wolverhampton) has 5 employees and maintains cash reserves of £760.3 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 292,049 | 363,913 | 995,623 | 879,122 | 849,685 | 849,907 | 320,837 | 272,449 | 206,766 | 264,982 | 261,177 | 244,645 | 225,430 | 223,020 | 173,765 |
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | |||||||||||||||
| Operating Profit | |||||||||||||||
| Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-Tax Profit | 50,534 | 116,721 | 146,339 | 81,780 | 68,550 | 105,880 | 5,869 | 12,286 | -7,487 | 86 | 8,227 | 3,715 | -3,041 | 8,175 | 4,795 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit After Tax | 50,534 | 116,721 | 146,339 | 81,780 | 68,550 | 105,880 | 5,869 | 12,286 | -7,487 | 86 | 8,227 | 3,715 | -3,041 | 8,175 | 4,795 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Profit | 50,534 | 116,721 | 146,339 | 81,780 | 68,550 | 105,880 | 5,869 | 12,286 | -7,487 | 86 | 8,227 | 3,715 | -3,041 | 8,175 | 4,795 |
| Employee Costs | 190,277 | 193,967 | 732,060 | 697,729 | 661,547 | 642,806 | 234,422 | 205,066 | 169,062 | 201,153 | 188,694 | 177,492 | 165,993 | 152,634 | 117,148 |
| Number Of Employees | 5 | 5 | 26 | 25 | 23 | 22 | 6 | 6 | 5 | 6 | 6 | 6 | 7 | 7 | 5 |
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 504 | 593 | 863 | 5,448 | 10,040 | 14,641 | 573 | 1,043 | 1,517 | 2,088 | 2,211 | 3,178 | 4,130 | 4,285 | 3,401 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 504 | 593 | 863 | 5,448 | 10,040 | 14,641 | 573 | 1,043 | 1,517 | 2,088 | 2,211 | 3,178 | 4,130 | 4,285 | 3,401 |
| Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Misc Debtors | 7,190 | 1,020 | 1,095 | 995 | 200,223 | 187,770 | 23,205 | 38,585 | 2,859 | 785 | 10,138 | 2,287 | 1,138 | 5,578 | 7,368 |
| Cash | 760,334 | 715,201 | 665,697 | 508,311 | 151,711 | 92,432 | 69,619 | 100,587 | 119,158 | 128,357 | 126,282 | 112,119 | 85,861 | 79,173 | 119,260 |
| misc current assets | 52,924 | 48,607 | 54,295 | 53,772 | 48,224 | 49,739 | 133,274 | 83,757 | 71,917 | 73,776 | 66,389 | 62,671 | 54,892 | 52,250 | 0 |
| total current assets | 820,448 | 764,828 | 721,087 | 563,078 | 400,158 | 329,941 | 226,098 | 222,929 | 193,934 | 202,918 | 202,809 | 177,077 | 141,891 | 137,001 | 126,628 |
| total assets | 820,952 | 765,421 | 721,950 | 568,526 | 410,198 | 344,582 | 226,671 | 223,972 | 195,451 | 205,006 | 205,020 | 180,255 | 146,021 | 141,286 | 130,029 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 2,840 | 2,160 | 69,722 | 63,160 | 2,160 | 9,579 | 2,993 | 10,180 | 5,784 | 5,993 | 20,480 | 13,660 | 1,920 | 1,786 | 1,704 |
| total current liabilities | 2,840 | 2,160 | 69,722 | 63,160 | 2,160 | 9,579 | 2,993 | 10,180 | 5,784 | 5,993 | 20,480 | 13,660 | 1,920 | 1,786 | 1,704 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 85,000 | 85,000 | 85,000 | 85,000 | 75,000 | 69,000 | 65,000 | 62,000 | 62,000 | 62,000 | 55,000 | 49,000 | 38,000 | 33,000 | 30,000 |
| total liabilities | 87,840 | 87,160 | 154,722 | 148,160 | 77,160 | 78,579 | 67,993 | 72,180 | 67,784 | 67,993 | 75,480 | 62,660 | 39,920 | 34,786 | 31,704 |
| net assets | 733,112 | 678,261 | 567,228 | 420,366 | 333,038 | 266,003 | 158,678 | 151,792 | 127,667 | 137,013 | 129,540 | 117,595 | 106,101 | 106,500 | 98,325 |
| total shareholders funds | 733,112 | 678,261 | 567,228 | 420,366 | 333,038 | 266,003 | 158,678 | 151,792 | 127,667 | 137,013 | 129,540 | 117,595 | 106,101 | 106,500 | 98,325 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | Mar 2012 | Mar 2011 | Mar 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | |||||||||||||||
| Depreciation | 89 | 270 | 4,585 | 4,592 | 4,601 | 4,725 | 470 | 474 | 571 | 1,059 | 967 | 1,338 | 1,476 | 1,493 | 3,018 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors | 6,170 | -75 | 100 | -199,228 | 12,453 | 164,565 | -15,380 | 35,726 | 2,074 | -9,353 | 7,851 | 1,149 | -4,440 | -1,790 | 7,368 |
| Creditors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 680 | -67,562 | 6,562 | 61,000 | -7,419 | 6,586 | -7,187 | 4,396 | -209 | -14,487 | 6,820 | 11,740 | 134 | 82 | 1,704 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | |||||||||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| share issue | |||||||||||||||
| interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from financing | 4,317 | -5,688 | 523 | 5,548 | -1,515 | 1,445 | 1,017 | 11,839 | -1,859 | 7,387 | 3,718 | 7,779 | 2,642 | 0 | 93,530 |
| cash and cash equivalents | |||||||||||||||
| cash | 45,133 | 49,504 | 157,386 | 356,600 | 59,279 | 22,813 | -30,968 | -18,571 | -9,199 | 2,075 | 14,163 | 26,258 | 6,688 | -40,087 | 119,260 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | 45,133 | 49,504 | 157,386 | 356,600 | 59,279 | 22,813 | -30,968 | -18,571 | -9,199 | 2,075 | 14,163 | 26,258 | 6,688 | -40,087 | 119,260 |
sickle cell and thalassaemia support project (wolverhampton) Credit Report and Business Information
Sickle Cell And Thalassaemia Support Project (wolverhampton) Competitor Analysis
Perform a competitor analysis for sickle cell and thalassaemia support project (wolverhampton) by selecting its closest rivals, whether from the HUMAN HEALTH AND SOCIAL WORK ACTIVITIES sector, other micro companies, companies in WV2 area or any other competitors across 12 key performance metrics.
sickle cell and thalassaemia support project (wolverhampton) Ownership
SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON) group structure
Sickle Cell And Thalassaemia Support Project (Wolverhampton) has no subsidiary companies.
Ultimate parent company
SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON)
03575079
sickle cell and thalassaemia support project (wolverhampton) directors
Sickle Cell And Thalassaemia Support Project (Wolverhampton) currently has 8 directors. The longest serving directors include Mr Clarence Crosdale (Jun 1998) and Mr Donald McIntosh (Jun 1998).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Clarence Crosdale | 69 years | Jun 1998 | - | Director | |
| Mr Donald McIntosh | United Kingdom | 67 years | Jun 1998 | - | Director |
| Mrs Dorothy McIntosh | England | 67 years | Sep 1998 | - | Director |
| Dr Deepak Kalra | 72 years | Mar 2004 | - | Director | |
| Mr Linton Bell | England | 68 years | Jan 2016 | - | Director |
| Mrs Loury Mooruth | England | 65 years | Mar 2018 | - | Director |
| Miss Diana Smith | England | 42 years | Aug 2022 | - | Director |
| Miss Anita Ezomon | England | 46 years | Sep 2023 | - | Director |
P&L
March 2024turnover
292k
-20%
operating profit
28.6k
0%
gross margin
38.4%
+1.73%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
733.1k
+0.08%
total assets
821k
+0.07%
cash
760.3k
+0.06%
net assets
Total assets minus all liabilities
sickle cell and thalassaemia support project (wolverhampton) company details
company number
03575079
Type
Private Limited by guarantee without Share Capital Exempt from using Limited
industry
86900 - Other human health activities
incorporation date
June 1998
age
27
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
March 2024
previous names
sickle cell and thalassaemia support project (September 1999)
accountant
NEIL HARRIS
auditor
-
address
paycare house george street, wolverhampton, WV2 4DX
Bank
LLOYDS TSB BANK PLC
Legal Advisor
WALL JAMES CHAPPELL
sickle cell and thalassaemia support project (wolverhampton) Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to sickle cell and thalassaemia support project (wolverhampton).
sickle cell and thalassaemia support project (wolverhampton) Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for SICKLE CELL AND THALASSAEMIA SUPPORT PROJECT (WOLVERHAMPTON). This can take several minutes, an email will notify you when this has completed.
sickle cell and thalassaemia support project (wolverhampton) Companies House Filings - See Documents
| date | description | view/download |
|---|
